Viread: profile and news
Patent Issue: AIDS shall cost dearer? May 14, 2006
...with patent offices in Kolkata and Delhi asking the government to prevent Gilead Sciences from patenting the antiretroviral drug Viread, available under the ... - International Reporter,
Additional oppn against AIDS drug patent May 13, 2006
...one of the largest generics companies in India, which is already marketing a generic version of tenofovir (tenofovir disoproxil fumarate or Viread), at a ... - Mid-Day Mumbai,
Foster City firm's AIDS drug ready for human trials May 12, 2006
...studies in Thailand, San Francisco and Atlanta, to see whether people can be shielded from the AIDS virus by one of the drugs in Truvada -- Viread, also known ... - San Jose Mercury News,
Activists: Deny patent to Gilead May 11, 2006
The aid organization Doctors Without Borders said Wednesday that Gilead's HIV drug Viread shouldn't get a patent in India because that would limit the ... - Inside Bay Area,
AHF APPLAUDS GILEAD SCIENCES FOR MOVE TO INCREASE GLOBAL ACCESS TO ... May 11, 2006
Sciences' announcement that it is pursuing non-exclusive, voluntary licensing to generic manufacturers in India for its AIDS drug Viread (tenofovir disoproxil ... - ITNews,
Human trials for promising AIDS drug May 12, 2006
...studies in Thailand, San Francisco and Atlanta to see whether people can be shielded from the AIDS virus by one of the drugs in Truvada - Viread, also known as ... - Advertiser Adelaide,
AIDS Groups in India Sue to Halt Patent for US Drug May 12, 2006
...groups asked Indian authorities to stop Gilead Sciences, a California biopharmaceutical company, from patenting the antiretroviral drug Viread — its brand ... - New York Times,
AIDS Groups in India Sue to Halt Patent for US Drug May 11, 2006
...patients-rights groups sued to stop Gilead Sciences, a California biopharmaceutical company, from patenting the antiretroviral drug Viread — the company's ... - New York Times,
HIV/AIDS Advocacy Groups File Opposition to Gilead's Request for ... May 12, 2006
...filed an opposition application with the New Delhi patent office to oppose Gilead's application to patent its antiretroviral drug Viread, known generically as ... - Kaiser network.org,
Bristol-Myers Squibb and Gilead Sciences Submit New Drug ... Apr 27, 2006
Truvada itself is a fixed-dose product that contains two of Gilead's anti-HIV medications, Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R ... - International News Service,
Drug firms seek to stop generic HIV treatment May 10, 2006
Gilead has sought a patent on a key Aids treatment called tenofovir (Viread), while Glaxo has sought one for a widely used drug called Combivir. ... - Guardian Unlimited,
Indians Protest Gilead Patent Application May 10, 2006
The Indian government is considering granting patent protection to the important second-line HIV treatment Viread, made by the US company Gilead Sciences ... - International News Service,
Panacos up on speculation of takeover May 8, 2006
Gilead makes the antiretrovirals Viread and Truvada, which combines the company's antiretroviral Emtriva along with Viread into a single daily tablet. ... - BusinessWeek
AIDS Drug Provokes Legal Fight in India May 11, 2006
..."We disagree with statements that Viread should not be patented; we believe that Viread represents innovation and is patentable under Indian law. ... - New York Times,
Gilead Sciences Announces First Quarter 2006 Financial Results Apr 18, 2006
HIV product franchise, including the continued robust performance of Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) and Viread(R) (tenofovir ... - Genetic Engineering News,
Protestors at Gilead Shareholders' Meeting May 10 May 9, 2006
Gilead's AIDS drugs Emtriva, Viread, and Truvada are life-saving medicines that could save the lives of millions of people around the world. ... - PR Newswire (press release),
Biotech Company Not Supplying AIDS Drug As Promised, Group Charges May 4, 2006
...has been accused of breaking its promise to make its anti-AIDS drug Viread widely available in developing countries, the Associated Press reported. ... - cybermed.it,
Natural Mutation Confers Drug Resistance on HBV Apr 26, 2006
Journal of Medicine. The virus in all three patients was sensitive to Viread (tenofovir), the authors reported. "Our observations ... - MedPage Today,
HIV Drugs Pace Gilead Apr 18, 2006
The drugs Truvada, Viread and Emtriva combined for $450.7 million in sales during the first quarter, up 50% from the $301.5 million for the same period last ... - TheStreet.com
Gilead Set For Further Upside On Strong HIV Franchise Apr 19, 2006
The analyst is bullish on the prospects for Gilead's triple combo HIV pill, which combines Viread and Emtriva with Bristol-Myers Squibb's Sustiva. ... - Forbes
Indians march on parliament over Aids drug patent May 10, 2006
...and the Delhi Network of Positive People this week registered a pre-grant opposition to the patenting of tenofovir disoproxil fumarate (Viread), an important ... - Financial Times,
Anti-AIDS campaigners protest against move to patent key anti ... May 10, 2006
The World Health Organisation (WHO) updated guidelines also recognizes the importance of TDF, marketed as Viread and recommends it for first and second line ... - NewKerala.com,
Gilead profit jumps, plans $500M stock buy back Apr 18, 2006
...year, to $248.9 million. Sales of Viread, another HIV drug, dropped 3 percent in the quarter, to $191.8 million. That drug is mostly ... - San Jose Business Journal,
BMS and Gilead submit HIV combination product for US approval Apr 28, 2006
Truvada itself is a fixed-dose product that contains two of Gilead's anti-HIV medications, Viread and Emtriva, in a single once-daily tablet. ... - Pharmaceutical Business Review
a cure for aids Apr 24, 2006
Researchers are also looking at giving tenofovir (also known by the brand name Viread) to uninfected men and women in pill form before sexual intercourse. ... - ProgressiveU.org,
Plans to Patent AIDS Drug Provoke Legal Fight in India Over Higher ... May 12, 2006
Two patients-rights groups sued to stop Gilead Sciences, a California biopharmaceutical company, from patenting the anti-retroviral drug Viread — the company ... - The MIT Tech,
Experts split on Gilead growth Apr 19, 2006
Gilead attributed the growth to 'robust performance of Truvada and Viread as well as continued strong product sales for Hepsera.'. ... - Monsters and Critics.com,
Liver transplantation can be successful in patients co-infected ... May 4, 2006
Three of these patients were resistant to 3TC, and received hepatitis B immunoglobulin (HBIG), 3TC and tenofovir (Viread) or adefovir (Hepsera). ... - Aidsmap,
Is diabetes a complication of HIV infection? May 7, 2006
...one week later, he started co-trimoxazole prophylaxis and an anti-HIV drug combination of 200mg FTC (emtricitabine, Emtriva), 300mg tenofovir (Viread) and six ... - Aidsmap,
Genzyme's First-Quarter Sales Below Expectations Apr 19, 2006
Credited for the good news were a boost in sales of the HIV therapies Viread (tenofovir disoproxil fumarate) and Truvada (a combination of Viread and ... - BioWorld Online (subscription),
Bristol, Gilead file for HIV combo drug approval Apr 27, 2006
Truvada, made by Gilead. Truvada is a fixed-dose product that contains two Gilead drugs: Viread and Emtriva. All three drugs work ... - Reuters
Gilead Sciences 1st-quarter profit rises 67 pct Apr 18, 2006
Sales of Viread and Emtriva, the two older HIV drugs used in the combination pill, fell 3 percent to $191.8 million and 20 percent to $10 million, respectively ... - Reuters
Gilead's Got Cash Up to the Gills Apr 19, 2006
The 50% increase in HIV product sales resulted from a 173% increase in sales of Truvada, a combination of two antiretrovirals, Emtriva and Viread, which the ... - Motley Fool
Gilead's Debt Sale Seen Fueling Potential Deals Apr 27, 2006
The triple combination HIV treatment, which consists of Viread and Emtriva from Gilead, along with Sustiva from Bristol-Myers Squibb (nyse: BMY - news - people ... - Forbes
Gilead records big rise in profit Apr 19, 2006
2005. Truvada combines Gilead's Viread and Emtriva HIV medicines, which the company also sells separately, into a once-daily pill. ... - Daily Review Online,
Starting treatment with Kaletra involves greater risk of increased ... Apr 24, 2006
...race, sex, age, CD4 cell count, duration of anti-HIV therapy or hepatitis C infection, the investigators noted that patients taking tenofovir (Viread and 3TC ... - Aidsmap,
Single-pill HIV therapy enters FDA hopper Apr 28, 2006
Squibb this week filed a New Drug Application with the US Food and Drug Administration to combine Gilead's Truvada (which itself combines Viread and Emtriva ... - Gay.com UK,
One-pill HIV regimen submitted for FDA review Apr 27, 2006
The tablet contains a full day’s dosing of Gilead’s drugs Viread and Emtriva—already packaged in a combination pill called Truvada—and BMS’s Sustiva. ... - The Advocate,
Gilead Sciences "buy," target price raised Apr 19, 2006
...its HIV franchise products. Sales of Truvada and Viread were ahead of the estimates, the analysts say. Gilead Sciences appears to ... - newratings.com
Gilead Sciences "buy" Apr 18, 2006
April 18. The analyst expects the sales of Gilead Sciences’ Truvada and Viread drugs to be ahead of the estimates. Gilead Sciences ... - newratings.com
National Roundup Apr 19, 2006
The two drugs are tenofovir ( Viread ) and emtricitabine, or FTC ( Emtriva ) , sold in combination as Truvada by Gilead Sciences Inc. ... - Windy City Times,
Variant of Hepatitis B Virus with Primary Resistance to Adefovir Apr 26, 2006
...resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to tenofovir (Viread, Gilead). All ... - New England Journal of Medicine (subscription),
